Glenmark Pharmaceuticals: A healthy bet
Focus on low-risk complex generics and speciality products are key positives
Indian pharma companies, caught in regulatory tangles and squeezed by pricing pressure in key markets, have been facing tough times of late. In particular, companies focussing on the US market have been hit hard. Such concerns have turned investors away from pharma stocks. But the steep correction in stock prices offers a good buying opportunity for investors with a long two to three-year time hor...
Please Wait while comments are loading...
This article is closed for comments.
Please Email the Editor
Comments to: web.businessline@thehindu.co.in
Copyright ©2018, The Hindu Business Line